Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

101. Ingenza’s Proprietary Technology Produces Novel Antimicrobial Peptide

Ingenza’s Proprietary Technology Produces Novel Antimicrobial PeptideIngenza is collaborating with researchers at Plymouth University to develop an efficient, scalable microbial production system for epidermicin, an exciting new antibiotic that rapidly kills methicillin-resistant Staphylococcus aureus (MRSA) and other harmful bacteria. Mathew Upton, Associate Professor in Medical Microbiology at Plymouth University, explained: “Epidermicin is a stable, 51 amino acid peptide originall


102. AstraZeneca Enhances Long-term Growth through Oncology Investment in A

AstraZeneca Enhances Long-term Growth through Oncology Investment in Acerta Pharma17/12/2015AstraZeneca today announced that it has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with a potential best-in-class irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cance


103. Ergomed plc Provides Update on Co-Development Partnerships.

Ergomed plc Provides Update on Co-Development Partnerships.16/12/2015Ergomed plc, (LSE: ERGO) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, provides an update on its current co-development partnerships. Ergomed’s four active partnerships have studies in late stage development with the potential to deliver significant Phase II and Phase III news flow with two studies scheduled to report resul


104. Malin Announces Investment in Gene Therapy Company Poseida Therapeutic

Malin Announces Investment in Gene Therapy Company Poseida Therapeutics, Inc.16/12/2015Malin Corporation plc. ("Malin"), an Irish-based global life sciences company, today announced that it has agreed to invest up to $30 million in Poseida Therapeutics, Inc. ("Poseida"), to acquire a shareholding of up to approximately 31%.Poseida is a US-based, privately-held human therapeutics company focused on the development of novel therapies using its ground-breaking proprietary genome engineering technol


105. Bayer and CRISPR Therapeutics AG Join Forces to Discover, Develop and

Bayer and CRISPR Therapeutics AG Join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases.21/12/2015The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from



Page 21 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019